EGFR and non-small cell lung carcinoma: Several clinical trials reported PD‐L1 expression was associated with EGFR+ and ALK+ in NSCLC with up to 72% and 78% of PD‐L1 positive rates in EGFR+ and ALK+ patients, respectively 31, 35, 41, 43.